Literature DB >> 19495885

Clinical significance of microvessel count in patients with metastatic liver cancer originating from colorectal carcinoma.

Atsushi Nanashima1, Kenichirou Shibata, Toshiyuki Nakayama, Syuuichi Tobinaga, Masato Araki, Masaki Kunizaki, Hiroaki Takeshita, Shigekazu Hidaka, Terumitsu Sawai, Takeshi Nagayasu, Toru Yasutake.   

Abstract

BACKGROUND: Microvessel count (MVC) has been correlated with patient prognosis in hepatocellular carcinoma. We investigated whether MVC assessed by staining with CD34 antibody was associated with disease-free and overall survival in patients with metastatic liver cancer (MLC).
METHODS: We examined relationships between MVC and clinicopathologic factors or postoperative outcomes in 139 MLC patients who underwent hepatectomy between 1990 and 2006. CD34 expression was analyzed by the immunohistochemical method.
RESULTS: MVC was associated with fibrous pseudocapsular formation on histological examination. By means of the modern Japanese classification of liver metastasis, poorer survival was associated with higher score, poorly differentiated adenocarcinoma, higher preoperative carcinoembryonic antigen (CEA) level, fibrous pseudocapsular formation, and smaller surgical margin. Shorter disease-free survival was associated with higher score when the Japanese classification of liver metastasis was used, multiple or bilobar tumor, regional lymph node metastasis in primary colon carcinoma, preoperative CEA level, fibrous pseudocapsular formation, and smaller surgical margin (<5 mm). Higher MVC (>or=406/mm(2)) was associated with decreased disease-free and overall survival by univariate analysis (P = .034 and P = .021, respectively), and higher MVC represented an independently poor prognostic factor in overall survival by Cox multivariate analysis (risk ratio, 2.71; P = .023) in addition to histological differentiation.
CONCLUSIONS: Tumor MVC seems to be a useful prognostic marker of MLC patient survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19495885     DOI: 10.1245/s10434-009-0459-8

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review.

Authors:  L Ung; A K-Y Lam; D L Morris; T C Chua
Journal:  Clin Transl Oncol       Date:  2014-01-24       Impact factor: 3.405

2.  Immunohistochemical analysis of vascular density and area in colorectal carcinoma using different markers and comparison with clinicopathologic prognostic factors.

Authors:  Luciana Regina Moreira; André Almeida Schenka; Paulo Latuf-Filho; André Lisboa Penná; Carmen S P Lima; Fernando Augusto Soares; Miriam Aparecida Silva Trevisan; José Vassallo
Journal:  Tumour Biol       Date:  2011-01-08

3.  Macrophage stimulating protein promotes liver metastases of small cell lung cancer cells by affecting the organ microenvironment.

Authors:  Seidai Sato; Masaki Hanibuchi; Takuya Kuramoto; Nodoka Yamamori; Hisatsugu Goto; Hirohisa Ogawa; Atsushi Mitsuhashi; Trung The Van; Soji Kakiuchi; Shin-ichi Akiyama; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2012-09-26       Impact factor: 5.150

4.  Prognostic implication of lymphatic vessel invasion in stage IB (pT2aN0M0) non-small cell lung cancer.

Authors:  Kunio Araki; Yoshin Adachi; Hiroyuki Metsugi; Takeshi Tokushima
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-09-14

Review 5.  The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.

Authors:  A A P Slesser; P Georgiou; G Brown; S Mudan; R Goldin; P Tekkis
Journal:  Clin Exp Metastasis       Date:  2012-11-23       Impact factor: 5.150

6.  Histopathological prognostic factors for colorectal liver metastases: A systematic review and meta-analysis of observational studies.

Authors:  Cássio Virgílio Cavalcante de Oliveira; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Evandro Sobroza de Mello; Fabricio Ferreira Coelho; Paulo Herman
Journal:  Histol Histopathol       Date:  2020-11-09       Impact factor: 2.303

7.  Characterizing venous vasculatures of hepatocellular carcinoma using a multi-breath-hold two-dimensional susceptibility weighted imaging.

Authors:  Shi-Xin Chang; Guan-Wu Li; Yao Chen; Hong Bao; Lei Zhou; Jun Yuan; Dong-Mei Wu; Yong-Ming Dai
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

8.  Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases.

Authors:  S De Bruyne; N Van Damme; P Smeets; L Ferdinande; W Ceelen; J Mertens; C Van de Wiele; R Troisi; L Libbrecht; S Laurent; K Geboes; M Peeters
Journal:  Br J Cancer       Date:  2012-05-17       Impact factor: 7.640

Review 9.  Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis.

Authors:  Yibaina Wang; Xiaoping Yao; Jie Ge; Fulan Hu; Yashuang Zhao
Journal:  ScientificWorldJournal       Date:  2014-03-27

10.  Differences in clinical characteristics and mutational pattern between synchronous and metachronous colorectal liver metastases.

Authors:  Peng Zheng; Li Ren; Qingyang Feng; Dexiang Zhu; Wenju Chang; Guodong He; Meiling Ji; Mi Jian; Qi Lin; Tuo Yi; Ye Wei; Jianmin Xu
Journal:  Cancer Manag Res       Date:  2018-08-27       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.